【摘要】 目的经导管肝动脉化疗栓塞(transarterial chemoembolizatin,TACE)包括传统TACE(cTACE)和载药微球TACE(DEB-TACE)。本研究旨在比较两种TACE疗法治疗不可切除肝细胞性肝癌(以下简称肝癌)的效果和安全性。方法检索电子全文数据库PubMed,纳入比较DEB-TACE和cTACE治疗不可切除肝癌疗效/安全性的随机对照研究(Randomized controlled trail, RCT),检索年限为建库至2019年6月30日。使用Review Manager 5.3软件分析数据。结果最终纳入4项随机对照研究,共纳入475例患者,其中231例接受DEB-TACE治疗,244例接受cTACE治疗。DEB-TACE组的肿瘤反应率、不良反应发生率和cTACE组相似,无明显差异(所有P>0.05)。结论 DEB-TACE和cTACE在治疗不可切除肝癌时具相似的安全性和有效性。更多还原

【Abstract】 Objective Transarterial chemoembolizatin(TACE) includes traditional TACE(cTACE) and drug-loaded microspheres TACE(DEB-TACE). The purpose of this study was to compare the efficacy and safety of the two TACE therapies for unresectable hepatocellular carcinoma(HCC).Methods PubMed, an electronic full-text database, was retrieved. Randomized controlled trail(RCT) was included to compare the efficacy and safety of DEB-TACE and cTACE in the treatment of unresectable hepatocellular carcinoma. The retrieval period was from the establishment of the database to 30 June 2019. Review Manager 5.3 software was hired to analyze data. Results Four randomized controlled trials were included. These studies included 475 patients, with 231 of whom were in DEB-TACE group and 244 were in cTACE group. There was no significant difference in tumor response rate and adverse reaction rate between DEB-TACE group and cTACE group(all P>0.05). Conclusion DEB-TACE and cTACE have similar safety and efficacy in treating unresectable HCC.更多还原